BRPI0823402A2 - Formulações farmacêuticas de olmesartan - Google Patents

Formulações farmacêuticas de olmesartan

Info

Publication number
BRPI0823402A2
BRPI0823402A2 BRPI0823402-7A BRPI0823402A BRPI0823402A2 BR PI0823402 A2 BRPI0823402 A2 BR PI0823402A2 BR PI0823402 A BRPI0823402 A BR PI0823402A BR PI0823402 A2 BRPI0823402 A2 BR PI0823402A2
Authority
BR
Brazil
Prior art keywords
olmesartan
pharmaceutical formulations
formulations
pharmaceutical
olmesartan pharmaceutical
Prior art date
Application number
BRPI0823402-7A
Other languages
English (en)
Inventor
Farhad Farshi
Recep Avci
Serdar Soylemez
Fikret Koc
Nadin Narsisoglu
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of BRPI0823402A2 publication Critical patent/BRPI0823402A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0823402-7A 2008-12-30 2008-12-30 Formulações farmacêuticas de olmesartan BRPI0823402A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/055572 WO2010076596A1 (en) 2008-12-30 2008-12-30 Pharmaceutical formulations of olmesartan

Publications (1)

Publication Number Publication Date
BRPI0823402A2 true BRPI0823402A2 (pt) 2015-06-16

Family

ID=40852166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0823402-7A BRPI0823402A2 (pt) 2008-12-30 2008-12-30 Formulações farmacêuticas de olmesartan

Country Status (9)

Country Link
US (1) US20110256221A1 (pt)
EP (1) EP2387392B1 (pt)
JP (1) JP2012513978A (pt)
BR (1) BRPI0823402A2 (pt)
CA (1) CA2748409C (pt)
EA (1) EA201170913A1 (pt)
ES (1) ES2404811T3 (pt)
TR (1) TR201109686T2 (pt)
WO (1) WO2010076596A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081376B2 (ja) * 2011-12-28 2017-02-15 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
CN102716100B (zh) * 2012-07-12 2013-08-07 南京正大天晴制药有限公司 一种含奥美沙坦酯的片剂及其制备方法
JPWO2014188729A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 経口用組成物
JP6653116B2 (ja) * 2014-08-27 2020-02-26 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
CN111557924B (zh) * 2020-05-13 2022-05-10 重庆赛凌医药有限公司 一种奥美沙坦酯氢氯噻嗪片的制备方法及奥美沙坦酯氢氯噻嗪片

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
CA2494707A1 (en) * 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CA2532450C (en) * 2003-07-16 2012-09-11 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
EP1784398A1 (en) * 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
US20060281800A1 (en) * 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
GB0710905D0 (en) * 2007-06-07 2007-07-18 Generics Uk Ltd Amorphous olmesartan medoxomil
WO2009113420A1 (ja) * 2008-03-13 2009-09-17 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善

Also Published As

Publication number Publication date
EP2387392A1 (en) 2011-11-23
TR201109686T2 (tr) 2012-03-21
EP2387392B1 (en) 2013-02-20
EA201170913A1 (ru) 2012-01-30
ES2404811T3 (es) 2013-05-29
WO2010076596A1 (en) 2010-07-08
US20110256221A1 (en) 2011-10-20
JP2012513978A (ja) 2012-06-21
CA2748409A1 (en) 2010-07-08
CA2748409C (en) 2016-03-08

Similar Documents

Publication Publication Date Title
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
LTPA2018005I1 (lt) Farmacinė kompozicija
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0721651A2 (pt) Composição farmacêutica
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
DK3097925T3 (da) Farmaceutisk sammensætning
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
SMT201400069B (it) Formulazione farmaceutica
BRPI1004940A2 (pt) composição farmacêutica
BRPI0814188A2 (pt) Formulações
BRPI1015939A2 (pt) composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0921313A2 (pt) composição farmaucêutica
DK2271618T3 (da) Farmaceutiske forbindelser
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0817053A2 (pt) Formulações farmacêuticas de orlistat
BRPI0912171A2 (pt) composição farmacêutica
BR112012003149A2 (pt) composição farmacêutica
BRPI0908455A2 (pt) formulações de flibanserina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.